Shandong Sito Bio-technology Co., Ltd. (SZSE:300583) agreed to acquire 60% stake in Yingu Pharmaceutical Co., Ltd. from Yingu Holding Group for approximately CNY 460 million on October 15, 2023. The transaction is approved by board of directors of Shandong Sito Bio-technology Co., Ltd. As of December 31, 2023, Yingu Pharmaceutical Co., Ltd. generated total assets of CNY 293.6 million, net assets of CNY 121.89 million, operating income of CNY 214.87 million, operating profit of CNY 12.31 million and net profit of CNY 13.95 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.82 CNY | -1.38% | -3.25% | -35.19% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-35.19% | 341M | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- 300583 Stock
- News Shandong Sito Bio-technology Co., Ltd.
- Shandong Sito Bio-technology Co., Ltd. agreed to acquire 60% stake in Yingu Pharmaceutical Co., Ltd. from Yingu Holding Group for approximately CNY 460 million.